Abstract
Introduction Disparities in healthcare access and clinical outcomes exist in individuals with type 1 diabetes (T1D) in less- versus well-resourced countries. An observational study of East African youth with T1D found an average haemoglobin A1c level of 11%. Blinded continuous glucose monitoring (CGM) demonstrated extremes of both hyper- and hypoglycemia. This randomised clinical trial (RCT) aims to test the hypothesis that enabling Ugandan youth with T1D to monitor glucose levels with CGM technology will improve glucose time-in-range (TIR, glucose levels 3.9-10.0 mmol/L).
Methods and Analysis Ugandan youth with T1D (n=180, age 4-26 years) will be randomized over five years, August 15, 2022-August 14, 2027, at Mulago or Nsambya Hospitals, Kampala. Half will be placed on unblinded Freestyle Libre 2 CGM for 12 months. The other half will be given sufficient test strips for 3x daily self-monitoring of blood glucose (SMBG) while wearing blinded CGM for 6 months (control group). Current standard-of-care is 2-3 test strips per day. The control group will switch to unblinded CGM months 7-12. All subjects will receive monthly diabetes education. The primary endpoints are 1) the 6-month change from baseline in glucose TIR in those wearing the unblinded CGM compared to those performing SMBG, and 2) cost analysis of CGM compared to 3x/day SMBG, to determine whether this technology is cost effective in a less-resourced country. The primary hypotheses will be tested by linear mixed effects models.
Ethics and Dissemination The protocol was approved by the Mulago Hospital Research Ethical Committee (MHREC 2173), Uganda National Council of Science and Technology (HS2129ES), and the University of Minnesota IRB (STUDY00013430). Results will be disseminated at scientific meetings, policy briefings at the Ugandan Ministry of Health, and peer reviewed journal publications.
Clinicaltrials.gov registration NCT05454176
Protocol Version 4.0, December 5, 2022
Strengths and Limitations of this Study
The study will be conducted at the two largest diabetes clinics in Uganda, involving a large number and wide age range of children and young adults from a less-resourced nation.
All participants will receive extensive diabetes education.
The University of Minnesota will monitor the study and will provide ongoing research education, training the Ugandan team for involvement in this and future RCTs.
The inclusion of Ministry of Health economists allows assessment of the real-world practicality of this intervention.
The study is being conducted in an urban setting, with no rural comparison.
Competing Interest Statement
AM and TP-W have received funding from Abbott Diabetes Care to perform a separate study of variability in the relation between CGM average glucose and HbA1c in Ugandan youth.
Clinical Trial
NCT05454176
Funding Statement
This work is supported by the National Institutes of Health, Grant # R01DK126726 (USA PI-Moran, Uganda PI-Piloya-Were). Abbott Diabetes Care is donating the Freestyle Libre 2 and Libre Pro sensors; they were not involved in the design of the study and will not be involved in data interpretation or reporting.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MULAGO HOSPITAL RESEARCH ETHICS COMMITTEE, KAMPALA , UGANDA APPROVED THE STUDY .
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study will be available upon reasonable request to the authors
